These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 34030480)

  • 1. Influence of Pattern Recognition Receptor Ligands on Induction of Innate Immunity and Control of Hepatitis B Virus Infection.
    Asadi-Asadabad S; Sarvnaz H; Amiri MM; Mobini M; Khoshnoodi J; Hojjat-Farsangi M; Jeddi-Tehrani M; Golsaz-Shirazi F; Shokri F
    Viral Immunol; 2021 Oct; 34(8):531-541. PubMed ID: 34030480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HBV Bypasses the Innate Immune Response and Does Not Protect HCV From Antiviral Activity of Interferon.
    Mutz P; Metz P; Lempp FA; Bender S; Qu B; Schöneweis K; Seitz S; Tu T; Restuccia A; Frankish J; Dächert C; Schusser B; Koschny R; Polychronidis G; Schemmer P; Hoffmann K; Baumert TF; Binder M; Urban S; Bartenschlager R
    Gastroenterology; 2018 May; 154(6):1791-1804.e22. PubMed ID: 29410097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unusual Features of Sodium Taurocholate Cotransporting Polypeptide as a Hepatitis B Virus Receptor.
    Li J; Zong L; Sureau C; Barker L; Wands JR; Tong S
    J Virol; 2016 Sep; 90(18):8302-13. PubMed ID: 27384660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct antiviral properties of TLR ligands against HBV replication in immune-competent hepatocytes.
    Lucifora J; Bonnin M; Aillot L; Fusil F; Maadadi S; Dimier L; Michelet M; Floriot O; Ollivier A; Rivoire M; Ait-Goughoulte M; Daffis S; Fletcher SP; Salvetti A; Cosset FL; Zoulim F; Durantel D
    Sci Rep; 2018 Mar; 8(1):5390. PubMed ID: 29599452
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Tu T; Zehnder B; Qu B; Urban S
    JHEP Rep; 2021 Feb; 3(1):100195. PubMed ID: 33385130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toll-like receptor 7 agonist GS-9620 induces prolonged inhibition of HBV via a type I interferon-dependent mechanism.
    Niu C; Li L; Daffis S; Lucifora J; Bonnin M; Maadadi S; Salas E; Chu R; Ramos H; Livingston CM; Beran RK; Garg AV; Balsitis S; Durantel D; Zoulim F; Delaney WE; Fletcher SP
    J Hepatol; 2018 May; 68(5):922-931. PubMed ID: 29247725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Novel vector preS1-tp fusion protein effectively inhibits hepatitis B virus replication and cccDNA synthesis by mediating hepatitis B virus targeting sequence small interfering RNA].
    Zeng YL; Gao F; Zhang C; Wei JF; Ma L; Ding GG; Li W; Shang J; Kang Y
    Zhonghua Gan Zang Bing Za Zhi; 2021 Feb; 29(2):126-132. PubMed ID: 33685080
    [No Abstract]   [Full Text] [Related]  

  • 8. Cellular DNA Topoisomerases Are Required for the Synthesis of Hepatitis B Virus Covalently Closed Circular DNA.
    Sheraz M; Cheng J; Tang L; Chang J; Guo JT
    J Virol; 2019 Jun; 93(11):. PubMed ID: 30867306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 5'-triphosphate-siRNA activates RIG-I-dependent type I interferon production and enhances inhibition of hepatitis B virus replication in HepG2.2.15 cells.
    Chen X; Qian Y; Yan F; Tu J; Yang X; Xing Y; Chen Z
    Eur J Pharmacol; 2013 Dec; 721(1-3):86-95. PubMed ID: 24099962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of pattern recognition receptor-mediated innate immunity inhibits the replication of hepatitis B virus in human hepatocyte-derived cells.
    Guo H; Jiang D; Ma D; Chang J; Dougherty AM; Cuconati A; Block TM; Guo JT
    J Virol; 2009 Jan; 83(2):847-58. PubMed ID: 18971270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The retinoic acid receptor (RAR) α-specific agonist Am80 (tamibarotene) and other RAR agonists potently inhibit hepatitis B virus transcription from cccDNA.
    Nkongolo S; Nußbaum L; Lempp FA; Wodrich H; Urban S; Ni Y
    Antiviral Res; 2019 Aug; 168():146-155. PubMed ID: 31018112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intrahepatic innate immune response pathways are downregulated in untreated chronic hepatitis B.
    Lebossé F; Testoni B; Fresquet J; Facchetti F; Galmozzi E; Fournier M; Hervieu V; Berthillon P; Berby F; Bordes I; Durantel D; Levrero M; Lampertico P; Zoulim F
    J Hepatol; 2017 May; 66(5):897-909. PubMed ID: 28043874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of hepatitis B virus through therapeutic activation of RIG-I and IRF3 signaling in hepatocytes.
    Lee S; Goyal A; Perelson AS; Ishida Y; Saito T; Gale M
    iScience; 2021 Jan; 24(1):101969. PubMed ID: 33458618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis B Virus Does Not Interfere With Innate Immune Responses in the Human Liver.
    Suslov A; Boldanova T; Wang X; Wieland S; Heim MH
    Gastroenterology; 2018 May; 154(6):1778-1790. PubMed ID: 29408639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon-inducible MX2 is a host restriction factor of hepatitis B virus replication.
    Wang YX; Niklasch M; Liu T; Wang Y; Shi B; Yuan W; Baumert TF; Yuan Z; Tong S; Nassal M; Wen YM
    J Hepatol; 2020 May; 72(5):865-876. PubMed ID: 31863794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Agonistic Activation of Cytosolic DNA Sensing Receptors in Woodchuck Hepatocyte Cultures and Liver for Inducing Antiviral Effects.
    Suresh M; Li B; Huang X; Korolowicz KE; Murreddu MG; Gudima SO; Menne S
    Front Immunol; 2021; 12():745802. PubMed ID: 34671360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insights on the antiviral mechanisms of action of the TLR1/2 agonist Pam3CSK4 in hepatitis B virus (HBV)-infected hepatocytes.
    Desmares M; Delphin M; Chardès B; Pons C; Riedinger J; Michelet M; Rivoire M; Verrier B; Salvetti A; Lucifora J; Durantel D
    Antiviral Res; 2022 Oct; 206():105386. PubMed ID: 35963549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toll-like receptor dual-acting agonists are potent inducers of PBMC-produced cytokines that inhibit hepatitis B virus production in primary human hepatocytes.
    Janovec V; Hodek J; Clarova K; Hofman T; Dostalik P; Fronek J; Chlupac J; Chaperot L; Durand S; Baumert TF; Pichova I; Lubyova B; Hirsch I; Weber J
    Sci Rep; 2020 Jul; 10(1):12767. PubMed ID: 32728070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA Polymerase κ Is a Key Cellular Factor for the Formation of Covalently Closed Circular DNA of Hepatitis B Virus.
    Qi Y; Gao Z; Xu G; Peng B; Liu C; Yan H; Yao Q; Sun G; Liu Y; Tang D; Song Z; He W; Sun Y; Guo JT; Li W
    PLoS Pathog; 2016 Oct; 12(10):e1005893. PubMed ID: 27783675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EGF receptor inhibitors comprehensively suppress hepatitis B virus by downregulation of STAT3 phosphorylation.
    Gan CJ; Li WF; Li CN; Li LL; Zhou WY; Peng XM
    Biochem Biophys Rep; 2020 Jul; 22():100763. PubMed ID: 32322693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.